The AVA Pharmaceuticals (Pvt) Ltd state pharmaceutical company reported the issue of an additional bundle of shares. The nominal value per share is $2. The total amount of additional shares is about 20 000 000 shares.
At present, the European founders, who also have shares in other pharmaceutical companies, hold 49% of AVA Pharmaceuticals (Pvt) Ltd’s shares. One of these investors is Dr. Reddy’s, a famous generic preparations producer. Increasing the flow of investment becomes possible due to the sale of the extra bundle of shares to investors. Moreover, it will make it possible to extend the production and kick-start the manufacture of the new medicines.
For today, the pharmaceutical company manufacturer over 200 types of generics. Among them are drugs against viral hepatitises, diabetes, human immunodeficiency virus, gastrointestinal disorders, and erectile dysfunction.
AVA Pharmaceuticals (Pvt) Ltd also negotiates for acquiring the patent right to manufacture Edurant, Juluca, Odefsey generic preparations, which analogs are lacking on the market for today. At the same time, the negotiations regarding obtaining the right to manufacture and release a generic drug are in progress with the Merck&Co American company, a Keytruda targeted medicine manufacturer. This drug is used in the treatment of oncology patients.
A flow of additional investments will make it possible to widen the range of manufactured products and increase the manufacturing rate of drugs.